NCT03128580

Brief Summary

The purpose of this study is to compare the number of euploid embryos obtained per metaphase II oocyte in unstimulated (modified natural cycles) and stimulated IVF cycles.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2017

Typical duration for all trials

Geographic Reach
1 country

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2017

Completed
11 days until next milestone

Study Start

First participant enrolled

April 21, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 25, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 7, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 3, 2020

Completed
Last Updated

July 23, 2020

Status Verified

July 1, 2020

Enrollment Period

3 years

First QC Date

April 10, 2017

Last Update Submit

July 21, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comparison of the number of euploid embryos from Metaphase II oocytes in different cohorts of embryos.

    Number of metaphase II oocyte per euploid embryo in unstimulated and stimulated cycles.

    30 days

Secondary Outcomes (2)

  • Incidence of embryo aneuploidies in two cohorts of embryos.

    30 days

  • Morphokinetic evaluation of embryos in two different cohorts of embryos.

    30 days

Study Arms (2)

Natural Cycle

The patient will not undergo hyperstimulation rather a natural cycle

Stimulated Cycle

The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.

Eligibility Criteria

Age30 Years - 38 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen undergoing fertility treatment
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Women undergoing In Vitro Fertilization treatment

You may qualify if:

  • Women
  • years old (inclusive)
  • with regular menstrual cycles (25-35 days)
  • AntiMülleriana Hormone \>5 pmol/L.
  • Undergoing IVF treatment

You may not qualify if:

  • BMI \>30 kg/m2
  • repeated miscarriages
  • implantation failure
  • uterine or adnexal pathology
  • Unable to be treated with gonadotrophins for the ovarian hyperstimulation
  • history of low response to ovarian hyperstimulation
  • participation in another study with PGS for monogenic pathology
  • Cryptozoospermia in male partner

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

IVI Valencia

Valencia, 46003, Spain

Location

Instituto Valenciano de Infertilidad Spain

Valencia, 46015, Spain

Location

IVI Valencia

Valencia, 46015, Spain

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2017

First Posted

April 25, 2017

Study Start

April 21, 2017

Primary Completion

April 7, 2020

Study Completion

July 3, 2020

Last Updated

July 23, 2020

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

Locations